Case 3: PACIFIC Trial in Unresectable Stage III NSCLC
Watch
Case 3: Chemoradiation for Stage III NSCLC
Case 3: Molecular Testing in Stage III NSCLC
Case 3: 63-Year-Old Man With Unresectable Stage IIIA NSCLC
Case 2: Treatment After Progression of EGFR+ NSCLC
Case 2: EGFR+ NSCLC Combination Therapies
Case 2: FLAURA Study for EGFR+ Metastatic NSCLC
Case 2: EGFR-Positive Non–Small Cell Lung Cancer
Case 2: Biomarker Testing for Non–Small Cell Lung Cancer
Case 2: 67-Year-Old Woman With EGFR+ Non–Small Cell Lung Cancer
Case 1: Small Cell Lung Cancer in the Era of Immunotherapy
Case 1: Biomarkers in Small Cell Lung Cancer
Case 1: CASPIAN Trial in Extensive-Stage Small Cell Lung Cancer
Case 1: IMpower133 Trial in Small Cell Lung Cancer
Case 1: Extensive-Stage Small Cell Lung Cancer Background
Case 1: 72-Year-Old Woman With Small Cell Lung Cancer
Clinical Cases in Lung Cancer
Experts in lung oncology review 3 clinical cases and discuss individualized treatment approaches for each patient.
Developing Therapeutic Strategies for Treating Accelerated and Blastic Phase MPN
Srdan Verstovsek, MD, PhD, shares his take home message from his presentation on accelerated and blastic phase myeloproliferative neoplasms during the first Annual Texas MPM Workshop.
Next Steps in Research in R/R MCL
R/R MCL: Applying Data Into Clinical Practice
R/R MCL: Treating With CAR-T
Rationale for CAR-T to Treat R/R MCL
Mantle Cell Lymphoma: Overview and Standard of Care
Case Overview: 66-Year-Old Woman With MCL
A 66-Year-Old Woman With Mantle Cell Lymphoma
Javier Munoz, MD, MS, FACP, of the Mayo Clinic, considers the appropriateness for CAR T-cell therapy for a 66-year-old woman with relapsed/refractory mantle cell lymphoma.
Selpercatinib Induced Durable Efficacy in RET Fusion-Positive NSCLC
Vivek Subbiah, MD, discusses the implications of the phase 1/2 LIBRETTO-001 study, which evaluated selpercatinib as treatment of patients with RET fusion-positive non–small cell lung cancer.
DTC Management: Advice and the Future of Treatment
TKI Therapy: Impact of Age and Adverse Events
Differentiated Thyroid Cancer: Initial Management
A 64-Year-Old Man With Differentiated Thyroid Cancer
